Tremfya is a fully-human, dual-acting monoclonal antibody that works by selectively targeting IL-23, a protein involved in abnormal immune activity. The drug is already approved in the US The post J&J’s Tremfya gets FDA approval for SC induction in active UC appeared first on Pharmaceutical Business review.